Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2021 07:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH

NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
November 15, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Announces New Long-Term Data Demonstrating Potential of Obeticholic Acid to Improve Transplant-Free Survival in Patients with PBC

Analysis compares findings from the long-term safety extension of the Phase 3 POISE trial to PBC natural history data from the Global PBC and UK-PBC databases Results will be featured in a...
November 11, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at Upcoming Investor Conferences

NEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
November 03, 2021 07:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

Worldwide Ocaliva® net sales of $92.8 million, representing 17% growth over the prior year quarter Company increases 2021 guidance of Ocaliva net sales to $355 million to $370 million and narrows...
November 02, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Announces Late-Breaking Oral Presentation and Poster Presentations at The Liver Meeting

Late-breaking oral presentation compares transplant-free survival in patients with PBC treated with OCA to external controls from the Global PBC and UK-PBC study groups Poster presentations describe...
October 27, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Announce Third Quarter 2021 Financial Results on November 3, 2021

NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
September 21, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at the 2021 Cantor Virtual Global Healthcare Conference

NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
September 13, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Announces Convertible Notes Repurchase

NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel...
September 01, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at the Virtual Baird 2021 Global Healthcare Conference

NEW YORK, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
August 10, 2021 21:43 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Announces Convertible Notes Exchange, New Issuance and Stock Repurchase

NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel...